The central aim is to assess how belimumab affects kidney function in patients with lupus nephritis.
Post hoc subgroup analysis from the phase III BLISS-LN trial
Focus on patients with lupus nephritis and impaired kidney function
Evaluation of clinical outcomes related to kidney health
Belimumab showed potential benefits in kidney function improvement.
Observed reduction in symptoms like haematuria and proteinuria.
Indicated decrease in the risk of kidney failure in treated patients.
Abstract
Lupus nephritis (LN) is one of the most serious complications of SLE, manifesting as haematuria and/or proteinuria, hypertension and ultimately kidney failure.